

DCF Psychotropic Medication Advisory Committee
February 1, 2013 1:00PM
Solnit Center for Children, Middletown, CT.
Meeting Notes

Present: Lesley Siegel, M.D. Chair; David Aresco, RPh; Chris Malinowski, APRN; Beth Muller, APRN; Joan Narad, M.D.; Amy Veivia, Pharm.D.; Patricia Cables, APRN; Jacqueline Harris, M.D.; Lee Combrinck-Graham, M.D.; Brian Keyes, M.D.; Allen Alton, M.D.; Debra Brown, M.D.; Irvin Jennings, M.D.; Pieter Joost Van Wattum, M.D.; Olumide O. Oluwabusi, M.D. (guest).

1. Call to order: Dr. Siegel called the meeting to order at 1:04pm.
2. Set date/time of next meeting: The next meeting is scheduled for March 1, 2013 from 1pm – 2:30pm, Solnit Center AB conference room.
3. Minutes: The minutes of the December 2012 meeting were reviewed, discussed and approved after several changes. The revised minutes will be sent to Dr. Siegel for approval and posting.
4. Announcements.
 - Revised 465: the new form was distributed, reviewed and discussed.
 - i. Noted that the 465 should also be completed when there is a change of service.
 - ii. Noted the 465 consent is valid for 1 year.
 - iii. Noted the CMCU may request studies be done (labs, EKG, etc.) but is not the repository for the results
5. Old Business:
 - Drug Use Guidelines: The changes recommended at the Dec 2012 PMAC were reviewed and approved. Additional recommendations include:
 - Unbold all lettering except headers.
 - Add warning “Take Seizure History” for all stimulants.
 - The footer “AVOID = Alternate medication suggested. Avoid use if possible” should be in smaller lettering.
 - Add Intuniv and Kapvay to the guideline.
 - The drug methylphenidate liquid extended release will be reviewed at the next meeting for possible inclusion on the approved drug list.
6. New Business
 - Use of PRNs in non-hospital settings - Defer

- Re-consideration of prazosin given increased requests and recently published article on use in children: Noted that CMCU is receiving an increased number of requests for the control of sleep disturbances related to trauma related PTSD.
 - There was a general discussion regarding the safety and efficacy of prazosin. This included a review of the article "Prazosin Treatment of Nightmares and Sleep Disturbances Associated with Posttraumatic Stress Disorder: Two Adolescent Cases" led by one of the authors Dr. Olumide O. Oluwabusi.
 - There was a general discussion regarding maximum dosing guidelines for prazosin.
 - PMAC recommendation: add to the approved drug list, the Drug Use Guidelines, and the Maximum dose guidelines.
 - i. Dosing recommendation: All patients will start with a 1mg/day dose. Maximum dosing then will be determined by age.
 1. <=6yrs old 2mg; >6yrs old and <=12yrs old 4mg; >10yrs old 10mg.
 - Recommend reviewing prazosin again at the Oct 2013 PMAC meeting (6 months time).
 - Adverse Drug Reaction aggregate report - Defer
 - Quantitative
 - Qualitative
7. Drug Information Inquiries (April 2012 – December 2012) - Defer
- From DI phone line:
 - From PMAC:
8. Adjournment: Dr. Siegel adjourned the meeting at 2:45pm.

Respectfully submitted:

David S. Aresco, Consulting Pharmacist